Keystone Symposia

This meeting took place in 2014

Here are the related meetings in 2021:
Antibodies as Drugs - RESCHEDULING IN PROGRESS (A6)

For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Prophylactic and Therapeutic Antibodies (Q3)

Organizer(s) Margaret Karow and Neil Stahl
February 9—14, 2014
Keystone Resort • Keystone, CO USA
Discounted Abstract Deadline: Oct 16, 2013
Abstract Deadline: Nov 14, 2013
Scholarship Deadline: Oct 16, 2013
Discounted Registration Deadline: Dec 10, 2013

Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc. and Roche. Supported by an educational grant from Lilly.

Summary of Meeting:
Until recently, most antibody therapeutics have been indicated for inflammatory diseases and cancer. The success of this approach has led to an expansion to a broader group of diseases such as infection, metabolic diseases, pain, Alzheimer’s and bone diseases, bringing a new level of challenge. This meeting will address developing antibodies for prophylactic- or chronic-use indications that have traditionally been dominated by small-molecule therapeutics, with case studies describing the development of antibodies for these marketplaces. It will also explore how molecule choices, dosing and delivery, and clinical design for efficacy and the minimization of safety risk, all impact success. The meeting will address up-and-coming approaches such as antibody engineering for pharmacokinetic and pharmacodynamic improvements, the use of vaccines to induce humoral responses in vivo, and use of antibodies to deliver vaccines, as well as look back at what has been learned from chronic therapy of immune diseases. We expect the attendees will be from the fields of translational medicine, antibody generation, pre-clinical pharmacology and clinical testing, whose work contributes to and drives innovation in these fields. It is anticipated that they will come away with an appreciation of these challenges and that the meeting will stimulate research and novel solutions for addressing this group of indications. Opportunities for interdisciplinary interactions will be significantly enhanced by the concurrent meeting on “Biology of B Cell Responses,” which will share a plenary session on antibody diversity.

View Meeting Program


National Institute of Allergy and Infectious Diseases (NIAID) Scholarship Recipients

Nathan J. Alves
Indiana University, USA

Erin Crossey
University of New Mexico, USA

Ashley S. Fink
University of North Dakota School of Medicine and Health Sciences, USA

Pramila Rijal
Weatherall Institute of Molecular Medicine, University of Oxford, UK